Phase 1b Evaluation of Bispecific T Cell Redirection Antibodies with Checkpoint Inhibitors in Relapsed/Refractory Multiple Myeloma Patients

The primary objective of this study is to evaluate the safety and efficacy of **bispecific T cell redirection antibodies** in combination with **checkpoint inhibition** for the treatment of participants with **relapsed or refractory multiple myeloma**. This is clinically relevant as it aims to address the therapeutic challenges faced by patients who have not responded to standard treatments or have experienced a recurrence of the disease. The study seeks to explore novel therapeutic strategies that could potentially improve patient outcomes in this difficult-to-treat population.

The clinical trial involves a total of **20 participants** diagnosed with **Relapsed or Refractory Multiple Myeloma**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific selection criteria are not provided. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not disclosed detailed inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the efficacy and safety of **bispecific T cell redirection antibodies** in combination with checkpoint inhibition for the treatment of participants with **relapsed or refractory multiple myeloma**. This study is a Phase 1b trial, characterized by a randomized, double-blind, and controlled design. The trial is expected to commence recruitment on July 19, 2022, and is projected to conclude by March 31, 2027. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to their continued eligibility and adherence to the study protocol.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful inclusion, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and to ensure their safety. These visits will include comprehensive assessments such as physical examinations, laboratory tests, and imaging studies as required by the protocol. The end-of-study visit marks the conclusion of a participant's involvement in the trial, during which final evaluations are conducted to gather data on the long-term effects of the treatment.

Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, if they withdraw consent, or if they fail to comply with the study requirements. The trial's methodology is structured to maintain scientific rigor and ensure the reliability of the data collected, contributing to the understanding of the therapeutic potential of the investigational treatment in the specified patient population.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 19, 2022, with an estimated completion date of March 31, 2027. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis throughout the study period. The focus will be on evaluating the treatment's impact on the specified medical condition, with results contributing to the understanding of the treatment's effectiveness in a controlled clinical setting.